MedTrace Logo

Therapeutic Drug Monitoring in Child and Adolescent Psychiatry

NCT01057329 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-03-06

No results posted yet for this study

Summary

The investigators aim to analyse in adolescents with mental illness effectiveness, side effects, and serum level concentrations of antipsychotics (olanzapine and aripiprazole), antidepressants (Duloxetine, Atomoxetine) by means of "Therapeutic Drug Monitoring" (TDM) in order to optimize dosage - effect relations and minimize unwanted side effects.

Conditions

Interventions

DRUG

Atomoxetine

mg according to body weight

DRUG

Duloxetine

30 mg / die

DRUG

Olanzapine

5mg 1 wwek and 10 mg from second week

DRUG

Aripiprazole

5 mg from week 1, 10 mg from week 2

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Andreas Karwautz, Prof · Medical University of Vienna

Eligibility

Min Age
10 Years
Max Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2019-03-05
Completion
2019-03-05

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01057329 on ClinicalTrials.gov